For how we live.
Talazoparib was already approved for castration-resistant disease. On 26 October the FDA cleared it earlier, in the hormone-sensitive, HRR-mutated setting, where TALAPRO-3 halved the risk of radiographic progression.
On 16 October the FDA converted pembrolizumab's accelerated approval for mutation-heavy solid tumours to full approval, but narrowed it: the qualifying threshold moved from 10 to 13 mutations per megabase.
GSK's PD-1 blocker won accelerated US approval on 19 October for previously untreated stage II/III dMMR rectal cancer. In the single-arm AZUR-1 trial, most patients avoided surgery, radiation and chemotherapy.
Thirteen years on, the independent DiAPREV-IT trial still shows no overall effect from GAD-alum. A 27-child genetic subgroup saw onset delayed — but the other subgroup got worse.
Using 245,388 genomes from the US All of Us programme, researchers built risk scores for 32 traits. More diversity helped prediction in under-represented groups — but a bigger sample was not always better.
Linking exome data to electronic medical records solved 15% of unexplained hearing-loss cases and flagged new candidate genes — while showing what the records could not supply.
SERENA-6 changed therapy the moment a resistance mutation appeared in the blood, not when tumours grew. It nearly doubled time to progression — and won camizestrant FDA approval in 2026.
The country's blood-spot programme has run since 2003 and reaches nearly every baby. A pilot adds genomic sequencing — where a study of Qatari genomes suggests the biggest gains lie.
A mandatory citywide programme sequenced 782 genes in 1,000 prospective couples. The at-risk rate was double that of a comparable Australian study, and most flagged couples still chose to marry.
A meta-analysis of 27 randomised trials found that disclosing a polygenic risk score did not meaningfully shift diet, screening uptake, medication use, anxiety or cholesterol.
Bizengri now covers NRG1-fusion cholangiocarcinoma, a mutation found in a fraction of a fraction of cases. The evidence is 19 patients, of whom about a third responded.
Two Nature papers describe the Taiwan Precision Medicine Initiative and the risk scores built from it. The genetic effects identified explained up to 10.3% of health variation in the cohort.